Fmr LLC Increases Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Fmr LLC increased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 330.6% in the third quarter, Holdings Channel.com reports. The fund owned 10,568 shares of the medical instruments supplier’s stock after acquiring an additional 8,114 shares during the quarter. Fmr LLC’s holdings in LeMaitre Vascular were worth $982,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of LMAT. SG Americas Securities LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $177,000. Hennion & Walsh Asset Management Inc. grew its position in LeMaitre Vascular by 62.2% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 10,289 shares of the medical instruments supplier’s stock worth $847,000 after buying an additional 3,947 shares in the last quarter. Fifth Third Bancorp increased its stake in LeMaitre Vascular by 6.6% in the 2nd quarter. Fifth Third Bancorp now owns 10,888 shares of the medical instruments supplier’s stock worth $896,000 after acquiring an additional 678 shares during the last quarter. Louisiana State Employees Retirement System boosted its position in shares of LeMaitre Vascular by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,100 shares of the medical instruments supplier’s stock valued at $831,000 after acquiring an additional 300 shares during the last quarter. Finally, West Oak Capital LLC bought a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at about $58,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of recent analyst reports. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $94.57.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Trading Down 8.5 %

LMAT opened at $92.10 on Tuesday. LeMaitre Vascular, Inc. has a 12 month low of $52.88 and a 12 month high of $109.58. The business’s 50-day moving average price is $97.65 and its 200-day moving average price is $89.62. The company has a market cap of $2.07 billion, a P/E ratio of 51.20, a P/E/G ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. During the same period in the previous year, the firm earned $0.33 EPS. The business’s quarterly revenue was up 15.6% on a year-over-year basis. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.69%. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.